Skip to main content
Signal8

New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology

$GILDPress releaseMay 21, 2026, 5:00 PM ETRead the release

Gilead and Kite will present more than 25 abstracts at ASCO and EHA 2026, highlighting momentum in antibody-drug conjugates and CAR T-cell therapy. Key data includes Phase 3 ASCENT-04 and ASCENT-03 analyses for Trodelvy in first-line metastatic triple-negative breast cancer, supporting potential label expansions and commercial growth.

Key figures

Abstract count
more than 25
Oral presentations
6
Gilead investment usd
32000000000
Trodelvy approval countries
more than 60
Trodelvy approval countries bc
more than 50

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.